Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3958997 | 0.83 | SIGMAR1 (0.66) | SIGMAR1GRIN2B | |
| SCHEMBL3450484 | 0.82 | DRD2 (0.49) | DRD2SLC6A4SLC6A3SIGMAR1HTR7 | |
| SCHEMBL5180843 | 0.78 | HRH3 (0.44) | SLC6A3SIGMAR1 | |
| SCHEMBL3917179 | 0.77 | DRD4 (0.46) | DRD2SLC6A4SLC6A3SIGMAR1HTR7 | |
| SCHEMBL3449498 | 0.75 | SIGMAR1 (0.50) | DRD2SLC6A4SLC6A3SIGMAR1HTR7 | |
| SCHEMBL8114316 | 0.73 | SLC6A3 (0.59) | DRD2SLC6A3SIGMAR1 | |
| SCHEMBL6944406 | 0.73 | SLC6A3 (0.59) | DRD2SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10464381 | 0.72 | SLC6A3 (0.58) | DRD2SLC6A3SIGMAR1 | |
| SCHEMBL3452566 | 0.72 | SIGMAR1 (0.46) | DRD2SLC6A4SLC6A3SIGMAR1HTR7 | |
| SCHEMBL18917601 | 0.69 | SLC6A3 (0.77) | DRD2SLC6A4SLC6A3SIGMAR1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820818-B2 | Heteroaryl nitrile derivatives | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| EP-1537111-A1 | HETEREOARYL NITRILE DERIVATIVES | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | CTSK, CTSS, CTSZ | DRD2 4486/4885SLC6A4 1648/4885SLC6A3 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.